Healthcare / Medical DevicesTaipei Exchange
$28.50
-0.40 (-1.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.0M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$384M
P/E
25.7x
↑EV/EBITDA
13.2x
↑ROE
5.5%
↑Gross Margin
74.1%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.8%
FCF CAGR
+27.3%
FCF margin
6.3%
FCF / Net income
1.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $448.8M · net income $15.1M · FCF $28.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $448.8M | $448.8M | $404.9M | $391.3M | $330.2M |
| Net Income | $15.1M | $15.1M | $8.4M | $9.2M | $8.0M |
| EBITDA | $34.5M | $34.5M | $26.9M | $29.8M | $27.9M |
| EPS | — | — | 0.62 | 0.68 | 0.59 |
| Gross Margin | 74.1% | 74.1% | 75.3% | 74.7% | 72.7% |
| Operating Margin | 4.1% | 4.1% | 1.9% | 2.8% | 2.4% |
| Net Margin | 3.4% | 3.4% | 2.1% | 2.4% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.49 | 0.50 | 0.52 |
| Cash Flow | |||||
| Free Cash Flow | $28.2M | $28.2M | $13.0M | $487000.00 | $13.7M |
| Returns | |||||
| ROE | 5.5% | 5.5% | 3.1% | 3.4% | 2.9% |
| Valuation | |||||
| P/E | 25.68 | 25.68 | 64.35 | 58.68 | 62.03 |
| EV/EBITDA | 13.24 | 13.24 | 23.30 | 20.86 | 19.99 |
| P/B | 1.40 | 1.40 | 2.00 | 1.97 | 1.79 |
| Growth & Yield | |||||
| Revenue Growth | 10.8% | 10.8% | 3.5% | 18.5% | — |
| EPS Growth | — | — | -8.8% | 15.3% | — |
| Dividend Yield | 3.6% | 3.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.62 → n/d
Residual
-9.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.